Cargando…

Canagliflozin mitigates ferroptosis and ameliorates heart failure in rats with preserved ejection fraction

Recently, hypoglycemic drugs belonging to sodium-glucose cotransporter 2 inhibitors (SGLT2i) have generated significant interest due to their clear cardiovascular benefits for heart failure with preserved ejection fraction (HFpEF) since there are no effective drugs that may improve clinical outcomes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Sai, He, Li-Li, Zhang, Guo-Rui, Zuo, Qing-Juan, Wang, Zhong-Li, Zhai, Jian-Long, Zhang, Ting-Ting, Wang, Yan, Ma, Hui-Juan, Guo, Yi-Fang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276585/ https://www.ncbi.nlm.nih.gov/pubmed/35476142 http://dx.doi.org/10.1007/s00210-022-02243-1

Ejemplares similares

Ferroptosis: The Potential Target in Heart Failure with Preserved Ejection Fraction
por: Li, Qing, et al.
Publicado: (2022)

Canagliflozin and irbesartan ameliorate renal fibrosis via the TGF-β1/Smad signaling pathway in Dahl salt-sensitive rats
por: Zhai, Jianlong, et al.
Publicado: (2023)

Resveratrol Ameliorates Cardiac Remodeling in a Murine Model of Heart Failure With Preserved Ejection Fraction
por: Zhang, Liyun, et al.
Publicado: (2021)

Canagliflozin mitigates ferroptosis and improves myocardial oxidative stress in mice with diabetic cardiomyopathy
por: Du, Shuqin, et al.
Publicado: (2022)

Effect of the Sodium-Glucose Cotransporter 2 Inhibitor Canagliflozin for Heart Failure With Preserved Ejection Fraction in Patients With Type 2 Diabetes
por: Ueda, Tomoya, et al.
Publicado: (2021)

Corrigendum: Resveratrol Ameliorates Cardiac Remodeling in a Murine Model of Heart Failure With Preserved Ejection Fraction
por: Zhang, Liyun, et al.
Publicado: (2022)

Endothelial-cell-mediated mechanism of coronary microvascular dysfunction leading to heart failure with preserved ejection fraction
por: Wang, Yong, et al.
Publicado: (2022)

An Effective Sodium-Dependent Glucose Transporter 2 Inhibition, Canagliflozin, Prevents Development of Hypertensive Heart Failure in Dahl Salt-Sensitive Rats
por: He, Lili, et al.
Publicado: (2022)

Personalized Management for Heart Failure with Preserved Ejection Fraction
por: Lin, Chang-Yi, et al.
Publicado: (2023)

Canagliflozin Attenuates Hepatic Steatosis and Atherosclerosis Progression in Western Diet-Fed ApoE-Knockout Mice
por: Zuo, Qingjuan, et al.
Publicado: (2022)

Heart failure with preserved ejection fraction
por: Rigolli, Marzia, et al.
Publicado: (2013)

Heart failure with preserved ejection fraction
por: ElGuindy, Ahmed, et al.
Publicado: (2012)

Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction
por: Kanagala, Prathap, et al.
Publicado: (2019)

Validation of heart failure algorithm for diagnosing heart failure with preserved ejection fraction: a meta‐analysis
por: Li, Shu, et al.
Publicado: (2023)

Ivabradine Ameliorates Cardiac Function in Heart Failure with Preserved and Reduced Ejection Fraction via Upregulation of miR-133a
por: Shao, Shuai, et al.
Publicado: (2021)

Prognostic Value of Anxiety Between Heart Failure With Reduced Ejection Fraction and Heart Failure With Preserved Ejection Fraction
por: Lin, Tin‐Kwang, et al.
Publicado: (2019)

Targeting efficacy of spironolactone in patients with heart failure with preserved ejection fraction: the TOPCAT study
por: Zhou, Hui‐min, et al.
Publicado: (2022)

Novel Mechanisms in Heart Failure With Preserved, Midrange, and Reduced Ejection Fraction
por: Lakhani, Ishan, et al.
Publicado: (2019)

Biomarkers in heart failure with preserved ejection fraction
por: Meijers, W. C., et al.
Publicado: (2016)

Management of heart failure with preserved ejection fraction
por: Gard, Emma, et al.
Publicado: (2020)

Managing heart failure with preserved ejection fraction
por: Davidson, Alexander, et al.
Publicado: (2020)

Biomarkers in Heart Failure with Preserved Ejection Fraction
por: Bayes-Genis, Antoni, et al.
Publicado: (2022)

Comorbidities in heart failure with preserved ejection fraction
por: Deichl, Andrea, et al.
Publicado: (2022)

Twist/untwist parameters are promising evaluators of myocardial mechanic changes in heart failure patients with preserved ejection fraction
por: Zhang, Yi, et al.
Publicado: (2020)

Blood pressure visit‐to‐visit variability and outcomes in patients with heart failure with preserved ejection fraction
por: Zhang, Qi, et al.
Publicado: (2021)

Seipin Knockout Mice Develop Heart Failure With Preserved Ejection Fraction
por: Bai, Bo, et al.
Publicado: (2019)

Heart failure with preserved ejection fraction and non‐alcoholic fatty liver disease: new insights from bioinformatics
por: Wang, Anzhu, et al.
Publicado: (2022)

Heart failure with preserved ejection fraction based on aging and comorbidities
por: Lin, Ying, et al.
Publicado: (2021)

Association of Systemic Trimethyllysine With Heart Failure With Preserved Ejection Fraction and Cardiovascular Events
por: Wei, Haoran, et al.
Publicado: (2022)

Rationale and Design of the CANONICAL Study　― Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Canagliflozin for Heart Failure With Preserved Ejection Fraction With Type 2 Diabetes Mellitus ―
por: Kasama, Shu, et al.
Publicado: (2019)

Outcome of Heart Failure with Preserved Ejection Fraction: A Multicentre Spanish Registry
por: Castillo, Juan C, et al.
Publicado: (2009)

Prevalence and Risk Factors of Heart Failure with Preserved Ejection Fraction: A Population-Based Study in Northeast China
por: Guo, Liang, et al.
Publicado: (2016)

The novel left atrial strain parameters in diagnosing of heart failure with preserved ejection fraction
por: Ma, Chang‐Sheng, et al.
Publicado: (2022)

Understanding Heart Failure With Preserved Ejection Fraction in a Diabetic Way
por: Li, Haobo, et al.
Publicado: (2021)

Melatonin improves cardiac function in a mouse model of heart failure with preserved ejection fraction
por: Liu, Yuan, et al.
Publicado: (2018)

Genetic architecture of heart failure with preserved versus reduced ejection fraction
por: Joseph, Jacob, et al.
Publicado: (2022)

An echo score raises the suspicion of cardiac amyloidosis in Chinese with heart failure with preserved ejection fraction
por: Yang, Hong, et al.
Publicado: (2022)

Effects of Kangdaxin on myocardial fibrosis in heart failure with preserved ejection fraction rats
por: Wu, Xiang, et al.
Publicado: (2022)

Weight Change and Mortality Risk in Heart Failure With Preserved Ejection Fraction
por: Huang, Peisen, et al.
Publicado: (2021)

Metabolomic Fingerprint of Heart Failure with Preserved Ejection Fraction
por: Zordoky, Beshay N., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_3ioqhurc8ldhvo0daapnkqefkr